Startup Capital Summit

3 Jun 2026 | Coimbra, Portugal

ServiceUpdated on 26 May 2026

TAPR

Marketing Trainee at Psychomeasure

Aveiro, Portugal

About

Class I SaMD platform that functions as a test for the mind, enabling early detection of psychosis risk through objective biomarkers assessment. With over 90% accuracy, it can predict the transition to psychosis up to two years before a clinical outbreak, while remaining completely language-independent.

Type

  • Pilot Projects, Testing & Validation
  • Business Development & Market Access
  • Partnerships & Collaborative Projects

Applies to

  • Healthcare & Life Sciences

Similar opportunities

  • Investment

    Pre-Seed Round

    • Pre-seed & Seed Funding
    • Healthcare & Life Sciences

    Andreia Pereira

    Marketing Trainee at Psychomeasure

    Aveiro, Portugal

  • Product

    [e-BIO.DocSign] & [e-BIO.Verify] — Next-Generation Electronic Signature & Document Authentication by [e-Security.BIO]

    • Financial Services
    • Defense & Security
    • Commerce & Consumer
    • Partnership building
    • Real Estate & PropTech
    • Healthcare & Life Sciences
    • Industrial & Manufacturing
    • Government & Public Sector
    • Legal, Compliance & RegTech
    • Pilot / validation opportunities
    • Business development / customers
    • Telecom & Digital Infrastructure
    • Strategic / institutional collaboration

    Frederico Laffitte

    CEO at e-Security EvoLegacy AI & BIO Solutions, Lda.

    Coimbra, Portugal

  • Service

    R&D + Outsourcing

    • Research, Development & Innovation
    • Pilot Projects, Testing & Validation
    • Partnerships & Collaborative Projects

    Henrique Ferreira

    Co-founder and CEO HFA Group at HFA,SA

    Agueda- Aveiro, Portugal